{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:42:08Z","timestamp":1793947328413,"version":"4.8.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["3UM1AI109565-08S1"],"award-info":[{"award-number":["3UM1AI109565-08S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL141934"],"award-info":[{"award-number":["R01 HL141934"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jconrel.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T07:17:59Z","timestamp":1704698279000},"page":"342-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Development of anti-PEG IgG\/IgM\/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy"],"prefix":"10.1016","volume":"366","author":[{"given":"Zhongbo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Starnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Talkington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosby A.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh K.","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P.","family":"Commins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2024.01.003_bb0005","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.jconrel.2024.01.003_bb0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/wnan.1157","article-title":"Recent advances in stealth coating of nanoparticle drug delivery systems","volume":"4","author":"Amoozgar","year":"2012","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2024.01.003_bb0015","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"9","key":"10.1016\/j.jconrel.2024.01.003_bb0020","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.jconrel.2024.01.003_bb0025","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1248\/bpb.b12-00276","article-title":"Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response","volume":"35","author":"Shimizu","year":"2012","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.003_bb0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s40883-021-00198-y","article-title":"Clinical relevance of pre-existing and treatment-induced anti-poly(ethylene glycol) antibodies","volume":"8","author":"Freire Haddad","year":"2022","journal-title":"Regen Eng. Transl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.003_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jconrel.2024.01.003_bb0040","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2024.01.003_bb0045","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.jconrel.2024.01.003_bb0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jconrel.2024.01.003_bb0055","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate hypersensitivity to polyethylene glycols and Polysorbates: more common than we have recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.jconrel.2024.01.003_bb0060","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.jaip.2019.12.041","article-title":"Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy","volume":"8","author":"Krantz","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.jconrel.2024.01.003_bb0065","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jaip.2020.11.011","article-title":"Anti-PEG IgE in anaphylaxis associated with polyethylene glycol","volume":"9","author":"Zhou","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2, Supplement","key":"10.1016\/j.jconrel.2024.01.003_bb0070","doi-asserted-by":"crossref","first-page":"AB232","DOI":"10.1016\/j.jaci.2022.12.722","article-title":"Genetic and epidemiologic risk associated with IgE-mediated anaphylaxis to polyethylene glycol","volume":"151","author":"Stone","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.003_bb0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cea.13995","article-title":"IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to mRNA COVID-19 vaccines","volume":"52","author":"Kelso","year":"2022","journal-title":"Clin. Exp. Allergy"},{"issue":"6","key":"10.1016\/j.jconrel.2024.01.003_bb0080","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cea.13874","article-title":"Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine","volume":"51","author":"Sellaturay","year":"2021","journal-title":"Clin. Exp. Allergy"},{"issue":"2","key":"10.1016\/j.jconrel.2024.01.003_bb0085","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jaip.2021.11.021","article-title":"Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: a case series","volume":"10","author":"Picard","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.jconrel.2024.01.003_bb0090","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.01.003_bb0095","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.vascn.2011.07.003","article-title":"A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers","volume":"64","author":"Liu","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"23","key":"10.1016\/j.jconrel.2024.01.003_bb0100","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"issue":"5","key":"10.1016\/j.jconrel.2024.01.003_bb0105","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2024.01.003_bb0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.toxrep.2020.12.022","article-title":"Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma","volume":"8","author":"Fang","year":"2021","journal-title":"Toxicol. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.003_bb0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000233512","article-title":"Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors","volume":"74","author":"Richter","year":"1984","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2024.01.003_bb0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.003_bb0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5415\/apallergy.2011.1.1.12","article-title":"Immunoglobulin E in health and disease","volume":"1","author":"Amarasekera","year":"2011","journal-title":"Asia Pac. Allergy"},{"issue":"7","key":"10.1016\/j.jconrel.2024.01.003_bb0130","first-page":"1556","article-title":"Reference values for serum IgE in Heathly non-atopic children and adults","volume":"28","author":"Dati","year":"1982","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.003_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13223-015-0106-9","article-title":"Anaphylaxis following a transvaginal ultrasound","volume":"12","author":"Jakubovic","year":"2016","journal-title":"Allergy, Asthma Clin. Immunol."},{"issue":"7","key":"10.1016\/j.jconrel.2024.01.003_bb0140","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4049\/immunohorizons.1900029","article-title":"Accelerated blood clearance of lipid nanoparticles entails a biphasic humoral response of B-1 followed by B-2 lymphocytes to distinct antigenic moieties","volume":"3","author":"Besin","year":"2019","journal-title":"ImmunoHorizons"},{"key":"10.1016\/j.jconrel.2024.01.003_bb0145","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.actbio.2023.08.052","article-title":"Pegloticase co-administered with high MW polyethylene glycol effectively reduces PEG-immunogenicity and restores prolonged circulation in mouse","volume":"170","author":"Li","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2024.01.003_bb0150","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jconrel.2021.08.051","article-title":"High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies","volume":"338","author":"Talkington","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.01.003_bb0155","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.08.017","article-title":"Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG","volume":"311-312","author":"McSweeney","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.01.003_bb0160","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ebiom.2018.10.038","article-title":"Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials","volume":"37","author":"Gupta","year":"2018","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.jconrel.2024.01.003_bb0165","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.anai.2021.09.012","article-title":"Non-immunoglobulin E-mediated allergy associated with Pfizer-BioNTech coronavirus disease 2019 vaccine excipient polyethylene glycol","volume":"127","author":"Jiang","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"8","key":"10.1016\/j.jconrel.2024.01.003_bb0170","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","article-title":"Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.jconrel.2024.01.003_bb0175","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11357-021-00495-y","article-title":"A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor","volume":"44","author":"Dezsi","year":"2022","journal-title":"Geroscience"},{"issue":"9937","key":"10.1016\/j.jconrel.2024.01.003_bb0180","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","article-title":"Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial","volume":"384","author":"Longo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2024.01.003_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/falgy.2021.715844","article-title":"Anaphylaxis to Pfizer\/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy","volume":"2","author":"McSweeney","year":"2021","journal-title":"Front. Allergy"},{"issue":"31","key":"10.1016\/j.jconrel.2024.01.003_bb0190","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1016\/j.vaccine.2023.06.009","article-title":"Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: evidence for immunogenicity of PEG","volume":"41","author":"Kozma","year":"2023","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.jconrel.2024.01.003_bb0195","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T16:33:00Z","timestamp":1738081980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":39,"alternative-id":["S0168365924000075"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.003","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of anti-PEG IgG\/IgM\/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}